CN203677610U - HCV specificity plasma adsorption column - Google Patents
HCV specificity plasma adsorption column Download PDFInfo
- Publication number
- CN203677610U CN203677610U CN201420024856.8U CN201420024856U CN203677610U CN 203677610 U CN203677610 U CN 203677610U CN 201420024856 U CN201420024856 U CN 201420024856U CN 203677610 U CN203677610 U CN 203677610U
- Authority
- CN
- China
- Prior art keywords
- adsorption column
- hepatitis
- blood
- plasma
- column cavity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000001179 sorption measurement Methods 0.000 title claims abstract description 114
- 229920000669 heparin Polymers 0.000 claims abstract description 59
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims abstract description 57
- 229960002897 heparin Drugs 0.000 claims abstract description 57
- 239000008280 blood Substances 0.000 claims abstract description 50
- 210000004369 blood Anatomy 0.000 claims abstract description 49
- 239000002245 particle Substances 0.000 claims abstract description 46
- 239000011347 resin Substances 0.000 claims abstract description 44
- 229920005989 resin Polymers 0.000 claims abstract description 44
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims abstract description 25
- 229910052744 lithium Inorganic materials 0.000 claims abstract description 25
- 239000003957 anion exchange resin Substances 0.000 claims abstract description 8
- 210000002381 plasma Anatomy 0.000 claims description 69
- 241000711549 Hepacivirus C Species 0.000 claims description 49
- 239000002253 acid Substances 0.000 claims description 20
- 239000011148 porous material Substances 0.000 claims description 7
- 125000003011 styrenyl group Chemical class [H]\C(*)=C(/[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 7
- 238000003466 welding Methods 0.000 claims description 4
- 238000009826 distribution Methods 0.000 claims description 3
- 230000001186 cumulative effect Effects 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 abstract description 28
- 230000023555 blood coagulation Effects 0.000 abstract description 3
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 abstract 2
- 238000011010 flushing procedure Methods 0.000 abstract 1
- 239000008187 granular material Substances 0.000 description 14
- 238000000034 method Methods 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- 230000008569 process Effects 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 7
- 239000003146 anticoagulant agent Substances 0.000 description 6
- 229940127219 anticoagulant drug Drugs 0.000 description 6
- 230000005611 electricity Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 208000005176 Hepatitis C Diseases 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 210000001772 blood platelet Anatomy 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 238000005202 decontamination Methods 0.000 description 4
- 230000003588 decontaminative effect Effects 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 210000003677 hemocyte Anatomy 0.000 description 4
- 229940000351 hemocyte Drugs 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000004080 punching Methods 0.000 description 4
- 238000010926 purge Methods 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 108091092724 Noncoding DNA Proteins 0.000 description 3
- 101710172711 Structural protein Proteins 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 241001536481 Banzi virus Species 0.000 description 2
- 206010011732 Cyst Diseases 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 241000710778 Pestivirus Species 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 208000031513 cyst Diseases 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 2
- 229960001008 heparin sodium Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 101710132601 Capsid protein Proteins 0.000 description 1
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229940074869 marquis Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- VBUNOIXRZNJNAD-UHFFFAOYSA-N ponazuril Chemical compound CC1=CC(N2C(N(C)C(=O)NC2=O)=O)=CC=C1OC1=CC=C(S(=O)(=O)C(F)(F)F)C=C1 VBUNOIXRZNJNAD-UHFFFAOYSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Images
Abstract
The utility model relates to the field of medical instruments, in particular to an HCV specificity plasma absorption column. The HCV specificity plasma absorption column comprises an absorption column cavity and resin particles arranged in the absorption column cavity, wherein the resin particles are made of macroporous strong base styrene anion exchange resin. A heparin lithium layer is attached to the inner wall of the absorption column cavity, and the thickness of the heparin lithium layer is 0.5mm-1mm. A plurality of absorption holes are distributed in each resin particle, and the diameter of each absorption hole is 62.5nm. The two ends of the absorption column cavity are respectively communicated with a blood catheter. Due to the electric property and the hole diameter, the resin absorption particles can be limited to absorb HCV particles only and will not absorb other non-HCV particles, which means selective absorption can be achieved. As the heparin lithium layer is evenly attached to the inner wall of the absorption column cavity, the adsorption column not only can resist blood coagulation but also can avoid pre-flushing and is easy to use.
Description
Technical field
This utility model relates to medical instruments field, in particular to a kind of hepatitis C virus specificity plasma adsorption column.
Background technology
Within 1974, first Golafield reports NANB-PTH.
American scientist Michael marquis in 1989 pauses (Michael Houghton) and his colleagues utilize a kind of new technological means---molecular biology method, finally found viral gene order, clone hepatitis C virus, and named primary disease and virus thereof for hepatitis C (Hepatitis C) and hepatitis C virus (HCV).Because HCV genome is similar with people's banzi virus and Pestivirus on structure and phenotypic characteristic, be classified as flaviviridae HCV.
HCV virion is spherical in shape, and diameter is less than 80nm, in hepatocyte, is 36～40nm, is 36-62nm in blood, is single strand plus RNA virus, holds the cyst membrane containing lipid outward at nucleocapsid, has furcella on cyst membrane.HCV only has Huh7, Huh7.5, and tri-kinds of cell in vitro culture systems of Huh7.5.1, chimpanzee can HCV infection, but symptom is lighter.
The nearly 9500-10000bp composition of gene structure: HCV-RNA, 5 ' 3 ' noncoding region (NCR) has respectively 319-341bp, and 27-55bp, contains forward several and inverted repeat, may be relevant with gene replication.An open reading frame (ORF) immediately in downstream, 5 ' noncoding region, wherein to put in order be 5 & apos to genome;-C-E1-E2/NS1-NS2-NS3-NS4-NS5-3 & apos; 3014 amino acid whose polyprotein precursors of the length of encoding, can be after host cell and viral oneself protease effect, be cracked into independent virus protein separately, i.e. three kinds of structural protein, for the nucleocapsid protein of molecular weight 19KD (or claims core protein, Core) and 33KD(E1), 72Kd(E2/NS1) glycoprotein, and four kinds of molecular weight non-structural protein that is 23KD, 52KD, 60KD, 116KD is corresponding with NS2, NS3, NS4, NS5 respectively.Because GP72 is just in time corresponding with Pestivirus surface protein or first non-structural protein of banzi virus (NS1), therefore by the genetic marker appellation E2/NS1 of GP72.E1 and E2/NS1 glycoprotein can produce the neutralization of anti-HCV.The function of NS2 and NS4 is not clear, finds to be closely linked with cell membrane.NS3 albumen has helicase activity, participates in untwisting HCV-RNA molecule, and to assist rna replicon, NS5 has the polymerase activity that depends on RNA, participates in HCV genome duplication.
Hepatitis C virus spreads by constantly copying original virus protein in the process of diffusion, and the thinking of the new treatment hepatitis C working out is at present that to cut off copying of hepatitis C virus in blood former.
But, existing adsorber can by the hepatitis C virus in blood with together with the useful albumen of human body, adsorb, in treatment, affected patient to nutraceutical absorption, cause patient at treatment health in mid-term because can not get enough nutritional supplementation, and reduced the immunity of self.
Utility model content
The purpose of this utility model is to provide a kind of hepatitis C virus specificity plasma adsorption column, to solve the above problems.
A kind of hepatitis C virus specificity plasma adsorption column providing in embodiment of the present utility model, comprising: adsorption column cavity and being located in described adsorption column cavity, the resin particle of being made up of macroporous strong basic styrene series anion exchange resin;
On the inwall of described adsorption column cavity, with Lithium acid heparin layer, the thickness of described Lithium acid heparin layer is 0.5-1mm;
On described resin particle, be distributed with multiple adsorption holes, the pore size of each described adsorption hole is 62.5nm;
The two ends of described adsorption column cavity are communicated with respectively blood catheter.
A kind of hepatitis C virus specificity plasma adsorption column that this utility model provides, in a cavity, be provided with the resin particle of being made by macroporous strong basic styrene series anion exchange resin, this resin particle band basic group is positive electricity, hepatitis C virus is with negative electricity, and the resin particle that is positive electricity with basic group can be by electronegative hepatitis C virus absorption.Resin absorption granule is provided with multiple adsorption holes simultaneously, the pore size of these adsorption holes is 62.5nm, for being slightly larger than the diameter of complete hepatitis C virus granule, this resin absorption granule can be limited and only be adsorbed hepatitis C virus granule by electrical and pore size thus, the granule that is not hepatitis C virus for other can not adsorb, and the hepatitis C virus specificity plasma adsorption column that namely this utility model provides can be realized optionally absorption.
Heparin is a kind of anticoagulant, is the polymer being alternately formed by connecting by two kinds of polysaccharide, has in vivo and in vitro blood coagulation resisting function.Lithium acid heparin is conventional anticoagulant heparin agent, and the sodium of heparin, potassium, lithium, ammonium salt are wherein best with Lithium acid heparin.On the inwall of adsorption column cavity, evenly with Lithium acid heparin layer, the heparin compositions in Lithium acid heparin layer is a kind of mucopolysaccharide that contains sulfate group, and with powerful negative charge, same sex electric charge repels each other, and can prevent that electronegative virus is attached to the inwall of adsorption column cavity; Can inhale mutually with the macroporous strong basic styrene series anion exchange resin adsorption particle of positively charged again, form the barrier being combined as a whole more closely and ensure more effectively viral adsorption simultaneously.Moreover, because heparin has the effect that stops thrombin to form, thereby stop platelet aggregation, so can make blood plasma can not form thrombosis in adsorption column; In addition, other adsorption column, in the used time, necessarily need to rush in advance multipass with heparin solution its heparinization could be used, but also need to give a certain amount of heparin of injection in patient body, make patient's whole body heparinization, and this adsorption column all entirely exempt from, not only can anticoagulation but also can be in order to avoid punching is in advance used simple.In sum, the Heterosis that has added the adsorption column of Lithium acid heparin obtains dripping showing fully.
When use this utility model to provide hepatitis C virus specificity plasma adsorption column time, first start blood extracorporeal circulation purifier normal saline blood catheter and this adsorption column rinsed one time, and then the decontamination cycle pattern that starts and enter blood plasma.Draw blood out from human body artery, use plasma separator that blood is separated, blood is divided into visible component hemocyte, as: erythrocyte, leukocyte, platelet etc. and aeriform part blood plasma.In visible component direct feedback body, the blood catheter that aeriform part blood plasma is communicated with by this adsorption column cavity one end enters in adsorption column, through resin absorption granule, by the hepatitis C virus absorption in blood plasma, the blood catheter being communicated with by the adsorption column cavity other end more afterwards feeds back human vein.When the cyclic process of blood plasma purging in vitro, directly inject heparin solution by transfusion device in to blood catheter in dosing place of the three-way valve of the nearly arterial end on blood vessel road, for anticoagulant.
First the blood of drawing from human body artery undertaken blood separation by plasma separator, visible component hemocyte wherein, as, erythrocyte, leukocyte, in the direct feedback bodies such as platelet, the blood catheter that aeriform part blood plasma is communicated with by this adsorption column cavity one end enters in adsorption column, through resin absorption granule, the hepatitis C virus in blood plasma is adsorbed, the blood catheter being communicated with by the adsorption column cavity other end more afterwards feeds back human vein, realize the specific selective absorption of adsorption column for hepatitis C virus, make hepatitis C patient's blood plasma obtain cleaning effectively.
And because be evenly equipped with Lithium acid heparin on this utility model adsorption column inwall, removed from the past other adsorption column will from low concentration heparin solution be flushed in advance high concentration heparin solution rush in advance some all over making the loaded down with trivial details of its heparinization, so also become very simple in operation.
In blood plasma purging in vitro cyclic process simultaneously, directly inject heparin solution by transfusion device in to blood catheter in dosing place of the three-way valve of the nearly arterial end on blood vessel road, this heparin solution is that about 500mL normal saline is joined 80mg heparin sodium and is mixed, and blood catheter transfusion drip speed is adjusted to approximately 30 droplets/minute.Like this need not be repeatedly pre-washing pipe road and adsorption column, also need not give first dose of heparin amount of injection in patient body, allows patient's whole body heparinization, also need not append heparin, and this process approximately can be saved 35 to 40 minutes times before the decontamination cycle of blood plasma.And blood plasma extracorporeal circulation on one side, add heparin on one side, giving first dose than conventional heparin, then to append the method in clinical application of a certain amount of heparin every half an hour more accurate, more efficient.
This using method is only applicable to this adsorption column, because this adsorption column is the adsorption column that has added Lithium acid heparin, exempts from pre-punching.
Brief description of the drawings
The structural representation of a kind of hepatitis C virus specificity plasma adsorption column that Fig. 1 provides for this utility model;
The sectional view of a kind of hepatitis C virus specificity plasma adsorption column that Fig. 2 provides for this utility model;
1. adsorption column cavity, 2. resin particle, 3. drainage screen, 4. seal cover, 5. blood plasma gateway, 6. blood catheter.
Detailed description of the invention
Also by reference to the accompanying drawings this utility model is described in further detail below by specific embodiment.
Embodiment 1: as depicted in figs. 1 and 2,
A kind of hepatitis C virus specificity plasma adsorption column, comprising: adsorption column cavity 1 and be located in described adsorption column cavity 1 resin particle 2 of being made up of macroporous strong basic styrene series anion exchange resin;
On the inwall of described adsorption column cavity 1, with Lithium acid heparin layer, the thickness of described Lithium acid heparin layer is 0.5-1mm;
On described resin particle 2, be distributed with multiple adsorption holes, the pore size of each described adsorption hole is 62.5nm;
The two ends of described adsorption column cavity 1 are communicated with respectively blood catheter 6.
A kind of hepatitis C virus specificity plasma adsorption column that this utility model provides, in a cavity, be provided with the resin particle 2 of being made by macroporous strong basic styrene series anion exchange resin, this resin particle 2 is with basic group to be positive electricity, hepatitis C virus is with negative electricity, and the resin particle 2 that is positive electricity with basic group can be by electronegative hepatitis C virus absorption.Resin absorption granule is provided with multiple adsorption holes simultaneously, the pore size of these adsorption holes is 62.5nm, for being slightly larger than the diameter of complete hepatitis C virus granule, this resin absorption granule can be limited and only be adsorbed hepatitis C virus granule by electrical and pore size thus, the granule that is not hepatitis C virus for other can not adsorb, the hepatitis C virus specificity plasma adsorption column that namely this utility model provides, in the time that blood plasma passes through, can realize the selective absorption to blood plasma.
Heparin is a kind of anticoagulant, is the polymer being alternately formed by connecting by two kinds of polysaccharide, has in vivo and in vitro blood coagulation resisting function.Lithium acid heparin is conventional anticoagulant heparin agent, and the sodium of heparin, potassium, lithium, ammonium salt are wherein best with Lithium acid heparin.On the inwall of adsorption column cavity 1, evenly has Lithium acid heparin layer, heparin compositions in Lithium acid heparin layer is a kind of mucopolysaccharide that contains sulfate group, with powerful negative charge, same sex electric charge repels each other, and can prevent that electronegative virus is attached to the inwall of adsorption column cavity 1; Can inhale mutually with the macroporous strong basic styrene series anion exchange resin adsorption particle of positively charged again, form the barrier being combined as a whole more closely and ensure more effectively viral adsorption simultaneously.Moreover, because heparin also has the effect that stops thrombin to form, thereby stop platelet aggregation, so can make blood plasma can not form thrombosis in adsorption column; In addition, other adsorption column, in the used time, necessarily need to rush in advance multipass with heparin solution its heparinization could be used, but also need to give a certain amount of heparin of injection in patient body, make patient's whole body heparinization, and this adsorption column all entirely exempt from, not only can anticoagulation but also can be in order to avoid punching is in advance used simple.In sum, the Heterosis that has added the adsorption column of Lithium acid heparin obtains dripping showing fully.
When use this utility model to provide hepatitis C virus specificity plasma adsorption column time, first start blood extracorporeal circulation purifier normal saline blood catheter 6 and this adsorption column rinsed one time, and then the decontamination cycle pattern that starts and enter blood plasma.Draw blood out from human body artery, use plasma separator that blood is separated, blood is divided into visible component hemocyte, as, erythrocyte, leukocyte, platelet etc. and aeriform part blood plasma.In visible component direct feedback body, the blood catheter 6 that aeriform part---blood plasma is communicated with by this adsorption column cavity 1 one end enters in adsorption column, through resin absorption granule, by the hepatitis C virus absorption in blood plasma, the blood catheter 6 being communicated with by adsorption column cavity 1 other end more afterwards feeds back human vein.When the cyclic process of blood plasma purging in vitro in dosing place of the three-way valve of the nearly arterial end on blood vessel road directly by transfusion device to the interior injection heparin solution of blood catheter 6, for anticoagulant.
First the blood of drawing from human body artery undertaken blood separation by plasma separator, visible component hemocyte wherein, as, erythrocyte, leukocyte, in the direct feedback bodies such as platelet, the blood catheter 6 that aeriform part blood plasma is communicated with by this adsorption column cavity 1 one end enters in adsorption column, through resin absorption granule, the hepatitis C virus in blood plasma is adsorbed, the blood catheter 6 being communicated with by adsorption column cavity 1 other end more afterwards feeds back human vein, realize the specific selective absorption of adsorption column for hepatitis C virus, make hepatitis C patient's blood plasma obtain cleaning effectively.
And because be evenly equipped with Lithium acid heparin on this utility model adsorption column inwall, removed from the past other adsorption column will from low concentration heparin solution be flushed in advance high concentration heparin solution rush in advance some all over making the loaded down with trivial details of its heparinization, so also become very simple in operation.
In blood plasma purging in vitro cyclic process simultaneously, in dosing place of the three-way valve of the nearly arterial end on blood vessel road directly by transfusion device to the interior injection heparin solution of blood catheter 6, this heparin solution is that about 500mL normal saline is joined 80mg heparin sodium and is mixed, and blood catheter 6 transfusion drip speeds are adjusted to approximately 30 droplets/minute.Pre-washing pipe road and adsorption column so repeatedly, also need not give first dose of heparin amount of injection in patient body, allow patient's whole body heparinization, also need not append heparin, this process approximately can be saved 35 to 40 minutes times before the decontamination cycle of blood plasma, and blood plasma extracorporeal circulation on one side, adds heparin on one side, giving first dose than conventional heparin, then to append the method in clinical application of a certain amount of heparin every half an hour more accurate, more efficient.
This using method is only applicable to this adsorption column, because this adsorption column is the adsorption column that has added Lithium acid heparin, exempts from pre-punching.
Embodiment 2:
According to above-described embodiment, this utility model has also done following improvement:
The two ends of described adsorption column cavity 1 are provided with blood plasma can be passed through, the intransitable drainage screen 3 of described resin particle 2 and seal cover 4, and described seal cover 4 is provided with blood plasma gateway 5;
Described drainage screen 3 is wrapped in the two ends of described adsorption column cavity 1, and described seal cover 4 is located at the outermost at the two ends of described adsorption column cavity 1, and the outer wall of the inwall of described seal cover 4 and described adsorption column cavity 1 is tightly connected; Described blood catheter 6 is communicated with described blood plasma gateway 5 respectively.
For in processing adsorption column cavity 1, resin particle 2 can be packed in adsorption column cavity 1, what adsorption column cavity 1 can be sealed is fine simultaneously, establish seal cover 4 at the two ends of adsorption column cavity 1, seal cover 4 is provided with blood plasma gateway 5, by this blood plasma gateway 5, the two ends of adsorption column cavity 1 are communicated with respectively blood catheter 6.
Can realize in the process of plasma purification in order to make adsorption column cavity 1, adsorption particle wherein can not dropped out, the two ends of adsorption column cavity 1 are provided with blood plasma can be by, the intransitable drainage screen 3 of resin particle 2, described drainage screen 3 is wrapped in the two ends of described adsorption column cavity 1, described seal cover 4 is located at the outermost at the two ends of described adsorption column cavity 1, and the outer wall of the inwall of described seal cover 4 and described adsorption column cavity 1 is tightly connected.
In order to reach good adsorption efficiency, preferably, the cumulative volume that resin particle 2 is set is more than or equal to 1/2 of described adsorption column cavity 1 volume.
The particle diameter of each described resin particle 2 is identical.More closely neat for what can make to arrange between multiple resin particles 2, the particle diameter that each resin particle 2 can be set is identical.
Each resin particle 2 is uniform round shaped grain or even side grain.Preferably, for convenient processing, each resin particle 2 is set and is uniform round shaped grain.Each resin particle 2 also can be set and be uniform side's grain.Or the resin particle 2 that is other any shape all can.
The inwall welding of the blood plasma gateway 5 arranging on blood catheter 6 and seal cover 4.In order to improve the seal being connected between adsorption column cavity 1 and blood catheter 6, the inwall welding of the blood plasma gateway 5 on outer wall and the adsorption column cavity 1 of blood catheter 6 can be set.
The inwall of blood plasma gateway 5 is provided with for twisting with blood catheter 6 binding thread connecing.For can be at the initial stage that blood catheter 6 is set, loose blood catheter 6 can not come off easily, can on the inwall of blood plasma gateway 5, be provided for and blood catheter 6 is twisted the binding thread connecing.At the connection initial stage, by this binding thread, fastening the twisting of blood catheter 6 and blood plasma gateway 5 connect, carry out again afterwards welding.
The foregoing is only preferred embodiment of the present utility model and with, be not limited to this utility model, for a person skilled in the art, this utility model can have various modifications and variations.All within spirit of the present utility model and principle, any amendment of doing, be equal to replacement, improvement etc., within all should being included in protection domain of the present utility model.Any imitate, change on the aperture of absorbent particles all belongs to infringement.
Claims (8)
1. a hepatitis C virus specificity plasma adsorption column, is characterized in that, comprising: adsorption column cavity and being located in described adsorption column cavity, the resin particle of being made up of macroporous strong basic styrene series anion exchange resin;
On the inwall of described adsorption column cavity, with Lithium acid heparin layer, the thickness of described Lithium acid heparin layer is 0.5-1mm;
On described resin particle, be distributed with multiple adsorption holes, the pore size of each described adsorption hole is 62.5nm;
The two ends of described adsorption column cavity are communicated with respectively blood catheter.
2. a kind of hepatitis C virus specificity plasma adsorption column according to claim 1, is characterized in that,
The two ends of described adsorption column cavity are provided with blood plasma can be passed through, the intransitable drainage screen of described resin particle and seal cover, and described seal cover is provided with blood plasma gateway;
Described drainage screen is wrapped in the two ends of described adsorption column cavity, and described seal cover is located at the outermost at the two ends of described adsorption column cavity, and the outer wall of the inwall of described seal cover and described adsorption column cavity is tightly connected; Described blood catheter is communicated with described blood plasma gateway respectively.
3. a kind of hepatitis C virus specificity plasma adsorption column according to claim 1, is characterized in that,
The cumulative volume of described resin particle is more than or equal to 1/2 of described adsorption column cavity volume.
4. a kind of hepatitis C virus specificity plasma adsorption column according to claim 1, is characterized in that,
The particle diameter of each described resin particle is identical.
5. a kind of hepatitis C virus specificity plasma adsorption column according to claim 1, is characterized in that,
Described resin particle is layered distribution.
6. a kind of hepatitis C virus specificity plasma adsorption column according to claim 1, is characterized in that,
Each described resin particle is uniform round shaped grain or uniform side grain.
7. a kind of hepatitis C virus specificity plasma adsorption column according to claim 2, is characterized in that, the inwall welding of described blood catheter and described blood plasma gateway.
8. a kind of hepatitis C virus specificity plasma adsorption column according to claim 2, is characterized in that, the inwall of described blood plasma gateway is provided with for twisting with blood catheter the binding thread connecing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201420024856.8U CN203677610U (en) | 2014-01-15 | 2014-01-15 | HCV specificity plasma adsorption column |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201420024856.8U CN203677610U (en) | 2014-01-15 | 2014-01-15 | HCV specificity plasma adsorption column |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN203677610U true CN203677610U (en) | 2014-07-02 |
Family
ID=50999579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201420024856.8U Expired - Lifetime CN203677610U (en) | 2014-01-15 | 2014-01-15 | HCV specificity plasma adsorption column |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN203677610U (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103721307A (en) * | 2014-01-15 | 2014-04-16 | 倪自谦 | Hepatitis C virus specificity plasma adsorption column and using method thereof |
| CN104147653A (en) * | 2014-08-27 | 2014-11-19 | 珠海健帆生物科技股份有限公司 | Blood perfusion device having anti-coagulation function and controlled-release function and manufacturing method thereof |
| CN105510110A (en) * | 2014-10-14 | 2016-04-20 | 贝克顿·迪金森公司 | Blood sample management using open cell foam |
-
2014
- 2014-01-15 CN CN201420024856.8U patent/CN203677610U/en not_active Expired - Lifetime
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103721307A (en) * | 2014-01-15 | 2014-04-16 | 倪自谦 | Hepatitis C virus specificity plasma adsorption column and using method thereof |
| CN104147653A (en) * | 2014-08-27 | 2014-11-19 | 珠海健帆生物科技股份有限公司 | Blood perfusion device having anti-coagulation function and controlled-release function and manufacturing method thereof |
| CN105510110A (en) * | 2014-10-14 | 2016-04-20 | 贝克顿·迪金森公司 | Blood sample management using open cell foam |
| US11298061B2 (en) | 2014-10-14 | 2022-04-12 | Becton, Dickinson And Company | Blood sample management using open cell foam |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN203677610U (en) | HCV specificity plasma adsorption column | |
| Neto et al. | Incidence of and risk factors for hepatitis B virus and hepatitis C virus infection among haemodialysis and CAPD patients: evidence for environmental transmission | |
| CN103691016A (en) | Aids virus specific plasma adsorption column and application method thereof | |
| Bastos et al. | Hepatitis C virus: Promising discoveries and new treatments | |
| RU2016130573A (en) | DEVICE FOR PLASMAFERESIS | |
| CN103721307A (en) | Hepatitis C virus specificity plasma adsorption column and using method thereof | |
| CN104922147A (en) | New structure medical resin for eliminating high cholesterol | |
| CN203647775U (en) | Human immunodeficiency virus specificity plasma adsorption column | |
| CN203647774U (en) | Hepatitis c virus absorber absorber | |
| Noorali et al. | Of lives and livers: emerging responses to the hepatitis C virus | |
| CN203763561U (en) | HBV (hepatitis B virus) specific plasma adsorption column | |
| CN203647773U (en) | Anticoagulant preflush-free type plasma adsorbing column cavity | |
| CN203647776U (en) | Hepatitis D virus absorber | |
| CN106267410B (en) | HIV infection cell separator | |
| CN205885877U (en) | Plasma exchange, joint clean system of absorption | |
| CN103736161A (en) | Hepatitis delta virus specificity plasma adsorption column and using method for same | |
| CN103691017A (en) | Hepatitis B virus specificity plasma adsorption column and using method thereof | |
| CN203354984U (en) | Plasma exchange adsorption filtration purification system for preparing square plasma storage pond | |
| Cerdas-Quesada | Potential benefits of plasma exchange by apheresis on the treatment of severe Icteric Leptospirosis: Case report and literature review | |
| CN202069913U (en) | Disposable virus inactivation blood transfusion set | |
| JP2006505536A5 (en) | ||
| CN203139198U (en) | Simple blood purifier | |
| CN203354989U (en) | Hepatitis B virus adsorber | |
| CN203280813U (en) | Plasma exchange absorption filtering purifying system provided with plasma storage bag in matched mode | |
| CN204158791U (en) | For the device of hepatitis B virus in filtering blood |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term |
Granted publication date: 20140702 |
|
| CX01 | Expiry of patent term |